Trial reportAfrican health sciences2024
Chlorhexidine mouthwash and augmentin to prevent Alveolar Osteitis after removal of mandibular third molar: a three-arm placebo- controlled randomized clinical trial.
Trial report in African health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Expert consensus on the use of oral antiseptics in oral surgery: Evidence-based clinical practice guidelines.Medicina oral, patologia oral y cirugia bucal · 2026Guideline
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alveolar Osteitis (AO) is a complicated problem that particularly occurs following the surgical removal of teeth resulting in severe pain and repeated practice/hospital visits. Objectives: The aim of the study was to investigate the role of postoperative Chlorhexidine (CHX) plus Augmentin in preventing Alveolar Osteitis AO after mandibular third molars removal. Methods: A total of 191 patients were randomly allocated to the CHX group (66 patients) or CHX and Augmentin group (63 patients) and Placebo group (62 patients). One mandibular third molar was removed in one session where surgical standard procedure was followed. All patients were prescribed rescue medication for postoperative pain relief. A postoperative follow up examination was performed on the third and seventh day to evaluate the existing cases of AO. Results: Group 2 (CHX and Augmentin) showed a significant reduction in AO (P < 0.05) when compared with group 1 (CHX) and group 3 (placebo). Patients have reported CHX side effects like taste alteration, bad taste, and staining. Conclusion: The combination of CHX plus Augmentin may be useful in reducing the incidence of AO following mandibular third molars extraction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.